Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 5:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 4,085 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Steroid treatment Clear all
Terminated Phase 3 Interventional Results available

A Study to Evaluate Safety and Efficacy of Elagolix in Participants With Endometriosis With Associated Moderate to Severe Pain

NCT03343067
View directory record Official record
Conditions
Endometriosis
Interventions
elagolix, estradiol/norethindrone acetate (E2/NETA)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
37
States / cities
Anniston, Alabama • Tucson, Arizona • Little Rock, Arkansas + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 15, 2026, 5:30 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of LibiGel® for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women

NCT00613002
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
testosterone gel, placebo gel
Drug
Lead sponsor
BioSante Pharmaceuticals
Industry
Eligibility
30 Years to 65 Years · Female only
Enrollment
597 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
60
States / cities
Birmingham, Alabama • Hoover, Alabama • Huntsville, Alabama + 56 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2013 · Synced Oct 15, 2026, 5:30 PM EDT
Completed Phase 1 Interventional

Phase I & Biological Study of Etanercept & Weekly Docetaxel in Patients With Advanced Solid Tumors

NCT00201812
View directory record Official record
Conditions
Tumors
Interventions
Etanercept, Docetaxel, Dexamethasone
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Oct 15, 2026, 5:30 PM EDT
Completed Phase 2 Interventional Results available

An Efficacy and Safety Study of Intetumumab (CNTO 95) in Participants With Metastatic Hormone Refractory Prostate Cancer

NCT00537381
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Docetaxel, Prednisone, Intetumumab, Placebo
Drug · Biological
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
7
States / cities
Birmingham, Alabama • Los Angeles, California • San Bernardino, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 15, 2026, 5:30 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

DEXTENZA for the Treatment of Pain and Inflammation Following Surgical Trabeculectomy and Ahmed Valve Procedures

NCT05116345
View directory record Official record
Conditions
Glaucoma Following Surgery
Interventions
DEXTENZA, Topical Dexamethasone
Drug
Lead sponsor
Brian Jerkins, MD
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 11, 2021 · Synced Oct 15, 2026, 5:30 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Blocking Mifepristone Action With Progesterone

NCT03774745
View directory record Official record
Conditions
Pregnancy, Unwanted
Interventions
Mifepristone 200 MG, micronized Progesterone, Placebo oral capsule
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
3
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2020 · Synced Oct 15, 2026, 5:30 PM EDT
Recruiting Early Phase 1 Interventional

Efficacy of Intramuscular Steroid Injection for Chronic Cough.

NCT06634823
View directory record Official record
Conditions
Chronic Cough (CC), Laryngeal Disease, Coughing
Interventions
Triamcinolone Acetonide Injectable Suspension, Saline injection
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 15, 2026, 5:30 PM EDT
Active, not recruiting Phase 3 Interventional

Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery

NCT01953588
View directory record Official record
Conditions
Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Invasive Ductal Breast Carcinoma, Invasive Lobular Breast Carcinoma, Recurrent Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
fulvestrant, anastrozole
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
1,473 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
856
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 524 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 15, 2026, 5:30 PM EDT
Recruiting Phase 1Phase 2 Interventional

Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM

NCT06518551
View directory record Official record
Conditions
Myeloma, Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Elotuzumab, Iberdomide, Dexamethasone
Drug
Lead sponsor
Omar Nadeem, MD
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 15, 2026, 5:30 PM EDT
Completed Phase 2 Interventional

Treatment of Boys With Precocious Puberty

NCT00001202
View directory record Official record
Conditions
Precocious Puberty
Interventions
Spironolactone, Testolactone, Deslorelin
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1985 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 15, 2026, 5:30 PM EDT
Completed Phase 2 Interventional

Induction Intensification in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia

NCT00002756
View directory record Official record
Conditions
Leukemia
Interventions
filgrastim, asparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride, etoposide, leucovorin calcium, mercaptopurine, methotrexate, prednisone, therapeutic hydrocortisone, vincristine sulfate
Biological · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 1 Year
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2012
U.S. locations
128
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 114 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2014 · Synced Oct 15, 2026, 5:30 PM EDT
Terminated Phase 3 Interventional

GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer

NCT00089856
View directory record Official record
Conditions
Prostate Cancer
Interventions
Immunotherapy with allogeneic prostate vaccine, Chemotherapy (Taxotere and prednisone)
Biological · Drug
Lead sponsor
Cell Genesys
Industry
Eligibility
18 Years and older · Male only
Enrollment
626 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
83
States / cities
Alabaster, Alabama • Anchorage, Alaska • Glendale, Arizona + 71 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2008 · Synced Oct 15, 2026, 5:30 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

In-vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus

NCT01453140
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
Cyclophosphamide and Sirolimus, Low dose IL-2 with Cytoxan + Sirolimus, Low dose IL-2, low dose Vidaza, cyclophosphamide & Sirolimus, Low dose IL-2, Vidaza, Cytoxan & Sirolimus
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 15, 2026, 5:30 PM EDT
Completed Phase 2 Interventional Results available

Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis

NCT02385110
View directory record Official record
Conditions
Leukemia
Interventions
Alemtuzumab, Etoposide, Dexamethasone, Methotrexate, Phone Call, Tocilizumab
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 17, 2024 · Synced Oct 15, 2026, 5:30 PM EDT
Completed Phase 2 Interventional

T-cell Depleted Bone Marrow and G-CSF Stimulated Peripheral Stem Cell Transplantation From Related Donors in Treating Patients With Leukemia, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, or Aplastic Anemia

NCT00002718
View directory record Official record
Conditions
Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
anti-thymocyte globulin, filgrastim, cyclophosphamide, cytarabine, methylprednisolone, thiotepa, in vitro-treated bone marrow transplantation, in vitro-treated peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 49 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 23, 2015 · Synced Oct 15, 2026, 5:30 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Prochymal® Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute Graft Versus Host Disease (GVHD)

NCT00562497
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
Prochymal®, Placebo, Corticosteroid
Drug · Other
Lead sponsor
Mesoblast, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
45
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2022 · Synced Oct 15, 2026, 5:30 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Progesterone Effect on Individuals Diagnoses With AD and PTSD.

NCT02187224
View directory record Official record
Conditions
Alcohol Dependence, Post-Traumatic Stress Disorder (PTSD)
Interventions
Progesterone, Placebo (for Progesterone)
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 60 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 26, 2023 · Synced Oct 15, 2026, 5:30 PM EDT
Active, not recruiting Phase 3 Interventional

Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ)

NCT04474223
View directory record Official record
Conditions
AVB - Atrioventricular Block, Fetal AVB
Interventions
Dexamethasone, IVIG
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Female only
Enrollment
1,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
23
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 15, 2026, 5:30 PM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers

Study of Oral Dehydroepiandrosterone(DHEA) to Treat Previously Unexplained Infertility

NCT00650754
View directory record Official record
Conditions
Primary Ovarian Insufficiency, Unexplained Infertility
Interventions
Dehydroepiandrosterone, Placebo
Dietary Supplement · Other
Lead sponsor
Center for Human Reproduction
Other
Eligibility
21 Years to 37 Years · Female only
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 30, 2015 · Synced Oct 15, 2026, 5:30 PM EDT
Completed Phase 2 Interventional

Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12A

NCT01858922
View directory record Official record
Conditions
Hodgkin Disease
Interventions
ABVE-PC, DECA
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 12, 2024 · Synced Oct 15, 2026, 5:30 PM EDT
Recruiting Phase 1 Interventional

A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT04910568
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Cevostamab, Tocilizumab, Pomalidomide, Daratumumab, Dexamethasone
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
6
States / cities
Duarte, California • Irvine, California • Denver, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 15, 2026, 5:30 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Plus Filgrastim in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy

NCT00005810
View directory record Official record
Conditions
Prostate Cancer
Interventions
filgrastim, carboplatin, docetaxel, estramustine phosphate sodium
Biological · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
7
States / cities
San Francisco, California • Chicago, Illinois • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Oct 15, 2026, 5:30 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety, Pharmacokinetics, and Preliminary Efficacy of Isatuximab in Patients Awaiting Kidney Transplantation

NCT04294459
View directory record Official record
Conditions
Immune System Disorder
Interventions
Isatuximab SAR650984, Acetaminophen (paracetamol) or equivalent, Ranitidine or equivalent, Diphenhydramine or equivalent, Methylprednisolone or equivalent, Montelukast or equivalent
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
4
States / cities
San Francisco, California • Rochester, Minnesota • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 15, 2026, 5:30 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Cyclic Versus Daily Teriparatide on Bone Mass

NCT00668941
View directory record Official record
Conditions
Osteoporosis
Interventions
Teriparatide, Alendronate, Calcium, Vitamin D3
Drug · Dietary Supplement
Lead sponsor
Helen Hayes Hospital
Other
Eligibility
45 Years to 85 Years · Female only
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2017
U.S. locations
1
States / cities
West Haverstraw, New York
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Oct 15, 2026, 5:30 PM EDT